High Tower Advisors, LLC Aldeyra Therapeutics, Inc. Transaction History

High Tower Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 10, 2021	SELL	$6.31 - $8.13 $76,300 - $98,307	-12,092 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$4.0 - $7.53 $48,368 - $91,052	12,092 New	12,092 $90,000
Q1 2020 May 21, 2020	SELL	$1.62 - $6.4 $26,325 - $104,000	-16,250 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$4.73 - $7.98 $9,460 - $15,960	-2,000 Reduced 10.96%	16,250 $94,000
Q3 2019 Nov 12, 2019	BUY	$4.41 - $6.12 $15,435 - $21,420	3,500 Added 23.73%	18,250 $96,000
Q2 2019 Aug 13, 2019	SELL	$6.0 - $9.0 $9,000 - $13,500	-1,500 Reduced 9.23%	14,750 $89,000
Q3 2018 Nov 09, 2018	SELL	$6.8 - $14.35 $20,400 - $43,050	-3,000 Reduced 15.58%	16,250 $224,000
Q1 2018 May 15, 2018	BUY	$6.55 - $8.9 $19,650 - $26,700	3,000 Added 18.46%	19,250 $145,000
Q4 2017 Feb 14, 2018	SELL	$5.7 - $7.75 $76,380 - $103,850	-13,400 Reduced 45.19%	16,250 $111,000
Q3 2017 Nov 14, 2017	BUY	$3.9 - $10.8 $115,635 - $320,220	29,650	29,650 $214,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $288M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on High Tower Advisors, LLC with notifications on news.